Price
CHART BY
Frequently asked questions
What is XORTX's market capitalization?
The market capitalization of XORTX is $3.07M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for XORTX?
XORTX's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$2.744. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for XORTX's stock?
Currently, 1 analysts cover XORTX's stock, with a consensus target price of $70.00. Analyst ratings provide insights into the stock's expected performance.
What is the EBITDA for XORTX?
XORTX's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$3.81M. EBITDA measures the company's overall financial performance.
What is the free cash flow of XORTX?
XORTX has a free cash flow of -$5.06M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does XORTX have, and what sector and industry does it belong to?
XORTX employs approximately 3 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of XORTX's shares?
The free float of XORTX is 1.67M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $3.07M
- EPS (TTM)
- -$2.744
- Free Float
- 1.67M
- EBITDA (TTM)
- -$3.81M
- Free Cashflow (TTM)
- -$5.06M
Pricing
- 1D span
- $1.691$1.781
- 52W span
- $0.359$7.00
Analyst Ratings
The price target is $70.00 and the stock is covered by 1 analysts.
Buy
1
Hold
0
Sell
0
Information
XORTX Therapeutics, Inc. is a biopharmaceutical company. The firm engages in development and commercialization of innovative therapies. It focuses on drug therapies for rare orphan disease indications such as polycystic kidney disease, and the treatment of health consequences caused by chronic high serum uric acid or hyperuricemia, including Type 2 Diabetic Nephropathy, cardiovascular disease, and diabetes. The company was founded by Allen Davidoff on May 31, 2011 and is headquartered in Calgary, Canada.
- Employees
- 3
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- ISIN
- CA98420Q4051
- Primary Ticker
- XRTX
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet